A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90 Yttrium-Zevalin and the Redox-Modulating Agent, Motexafin Gadolinium (MGd)
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Motexafin gadolinium (Primary) ; Ibritumomab tiuxetan; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 12 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 11 Apr 2011 Planned End Date changed from 1 Jan 2011 to 1 Jan 2012. according to ClinicalTrials.gov.
- 11 Apr 2011 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov.